Score Overview
Explore the 2021 public Archive ranking →
Where Alnylam Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ALNY
2009: 17.7% · 2021: 28.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 255.36 | — |
1 Year2025-09-26 | $ 446.40 | -42.80% |
5 Years2021-09-28 | $ 177.08 | 44.21% |
10 Years2016-09-28 | $ 76.67 | 233.06% |
20 Years2006-09-28 | $ 14.48 | 17x |
All Time2004-05-28 | $ 6.01 | 42x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | All Time2004-05-28 |
|---|---|---|---|---|---|---|
| Price | $ 255.36 | $ 446.40 | $ 177.08 | $ 76.67 | $ 14.48 | $ 6.01 |
| Return | — | -42.80% | 44.21% | 233.06% | 17x | 42x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 4.80B | $ 807M | $ 3.30B |
| 2025 | $ 3.71B | $ 313M | $ 2.90B |
| 2024 | $ 2.24B | -$ 278M | $ 2.69B |
| 2023 | $ 1.82B | -$ 440M | $ 2.43B |
| 2022 | $ 1.03B | -$ 1.13B | $ 2.19B |
| 2021 | $ 844M | -$ 852M | $ 2.43B |
| 2020 | $ 492M | -$ 858M | $ 1.87B |
| 2019 | $ 219M | -$ 886M | $ 1.53B |
| 2018 | $ 74M | -$ 761M | $ 1.08B |
| 2017 | $ 89M | -$ 490M | $ 1.70B |
| 2016 | $ 47M | -$ 410M | $ 942M |
| 2015 | $ 41M | -$ 290M | $ 1.08B |
| 2014 | $ 50M | -$ 360M | $ 696M |
| 2013 | $ 47M | -$ 89M | $ 245M |
| 2012 | $ 66M | -$ 106M | $ 122M |
| 2011 | $ 82M | -$ 57M | $ 146M |
| 2010 | $ 100M | -$ 43M | $ 233M |
| 2009 | $ 100M | -$ 47M | $ 281M |
| 2008 | $ 96M | -$ 26M | $ 430M |
| 2007 | $ 50M | -$ 85M | $ 389M |
| 2006 | $ 26M | -$ 34M | $ 217M |
| 2005 | $ 5M | -$ 42M | $ 80M |
| IPO2004 | $ 4M | -$ 32M | $ 46M |
Alnylam Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 492M to $ 3.71B and net income went from -$ 858M to $ 313M. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 41M to $ 3.71B and net income went from -$ 290M to $ 313M. Revenue increased in 9 of those 10 years; net income in 6.
Alnylam Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.
Membership
Continue ALNY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
